- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00510783
IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
More than one in every one hundred patients presenting to the emergency department for care do so for seizures. More than half of these patients will require medications, often intravenously (IV), while in the emergency department. For many years the standard treatment has been phenytoin. However, there are many known contraindications to the use of this drug. These include known hypersensitivity, cardiac arrhythmias, cardiac disease, impaired liver or kidney function, diabetes mellitus, older age, thyroid disease, pregnancy, and alcohol use. A recent review of patients with seizure disorder at Emory Crawford Long and Emory University hospitals suggested that a significant percentage of those who were taking phenytoin actually had one or more of these contraindications. Additionally, the IV form of phenytoin has known, severe adverse effects including cardiovascular collapse, life threatening cardiac arrhythmias, and severe hypotension. There is another form of Phenytoin, called Fosphenytoin, that while safer in some respects still has similar concerns associated with its administration.
Levetiracetam (Keppra) has been available as an oral drug in the United States since 2000 and has a well established safety record when used as an add-on drug for patients with partial onset seizures. A double-blinded randomized study has shown that levetiracetam is also effective for primary generalized seizures as well.
The IV form of levetiracetam has recently been approved by the FDA for use. The only known contraindications other than known hypersensitivity include impaired renal function, psychiatric disorder, older age, and pregnancy. IV levetiracetam is not known to cause any of the acute, catastrophic events seen occasionally with phenytoin.
The investigators would therefore like to compare IV phenytoin and fosphenytoin to IV levetiracetam in preventing early recurrent seizures. Patients with known seizure disorders would be randomly assigned to one of two groups and therefore receive either IV fosphenytoin or IV levetiracetam. After an observation period, seizure free patients would be discharged and 24 hour phone follow up conducted to assess for the effectiveness of these anti-seizure medications as well as for any adverse reactions.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18 or older
- patient presenting to Grady Memorial Hospital's Emergency Department after having a tonic-clonic seizure (primary or secondarily generalized) within the last 4 hours
Cause of seizure for inclusion: reason for seizure is often undetermined at time of presentation to the Emergency Department. The most likely expected causes of a seizure are noncompliance to existing antiepileptic drug regimen, refractory epilepsy with breakthrough seizure, metabolic aberration, alcohol withdrawal, or unknown.
Exclusion Criteria:
- non-English speaking
- first time seizure
- seizures other than tonic-clonic seizure (primary or secondarily generalized)
- more than 3 seizures in 24 hours or status epilepticus, pregnant patients by history or by urine pregnancy testing, serious neurologic insult resulting in seizure but where seizure is not the primary reason for admission (e.g. traumatic brain injury with seizure or hemorrhagic stoke would be excluded)
- contraindication to IV levetiracetam
- received IV phenytoin within 24 hours
- known allergy to phenytoin
- previously enrolled in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Phenytoin/Fosphenytoin
Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
|
IV load will be dependant on dilantin level.
If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
Other Names:
IV load will be dependant on dilantin level.
If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
Other Names:
|
Active Comparator: Levetiracetam
Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
|
The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced a Recurrent Seizure After Treatment.
Time Frame: 24 hours
|
Recurrent seizure is defined as a seizure within 24 hours of treatment in the Emergency Department.
|
24 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Debra Houry, MD, Emory University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Disease Attributes
- Emergencies
- Seizures
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Nootropic Agents
- Levetiracetam
- Phenytoin
- Fosphenytoin
Other Study ID Numbers
- IRB00002266
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tonic-clonic Seizure
-
Eisai Inc.CompletedSeizure Disorder Generalized Tonic Clonic
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, Clermont-FerrandUnknownCreatine Kinase | Lactate | Epileptic Seizure | Epileptic Generalized Tonic-clonic SeizureFrance
-
Michael A. Gelfand, MD, PhDEpilepsy FoundationCompletedGeneralized Tonic Clonic Seizure | Drug Resistant Epilepsy | Drop Seizures | Complex Partial Seizure | Fall Due to SeizureUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedGeneralized Tonic Clonic SeizuresKorea, Republic of, United States, Austria, Serbia, India, Spain, Poland, Malaysia, China, Bulgaria, Denmark, Greece, Hungary, United Kingdom, Belarus, France, Montenegro, Philippines, Romania, Russian Federation, Slovakia, Ukraine, Lebano... and more
-
Xenon Pharmaceuticals Inc.Worldwide Clinical TrialsRecruitingPrimary Generalized Tonic-Clonic SeizuresUnited States, Australia, Bulgaria, Poland, Czechia, Canada, Portugal, Croatia, Italy, Spain
-
Zogenix, Inc.RecruitingGeneralized Tonic Clonic Seizure | CDKL5 Deficiency Disorder | Epileptic Spasm | Refractory SeizuresUnited States, Japan, Germany, Netherlands, Portugal, Spain, Belgium, United Kingdom, Austria, Georgia, Israel, Ireland
-
GlaxoSmithKlineCompletedEpilepsy, Tonic-ClonicUnited States, Germany, Korea, Republic of, Chile, India, Russian Federation, Brazil, Ukraine, Puerto Rico, Argentina, Malaysia
-
Eisai Inc.CompletedPartial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized SeizuresUnited States
Clinical Trials on Fosphenytoin
-
NobelpharmaCompleted
-
Aatif HusainUCB PharmaCompletedNonconvulsive SeizuresUnited States
-
Danish Headache CenterCompleted
-
University of Alabama at BirminghamUCB PharmaTerminatedTraumatic Brain InjuryUnited States
-
University of VirginiaMedical University of South Carolina; National Institute of Neurological Disorders... and other collaboratorsCompletedBenzodiazepine Refractory Status EpilepticusUnited States
-
Jed E. RoseNational Institute on Drug Abuse (NIDA); Philip Morris USA, Inc.CompletedNicotine DependenceUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Columbia UniversityTerminatedLymphoma | Leukemia | Anemia | Neuroblastoma | ImmunodeficienciesUnited States